Tracer to diagnose Parkinson’s via PET scans moving into clinical trial

The Center Without Walls consortium, supported by a $30 million grant from the National Institute of Neurological Disorders and Stroke (NINDS), is advancing efforts to improve the diagnosis and monitoring of neurological diseases, including Parkinson’s. Led by the University of Pennsylvania’s medical school, the consortium is preparing to launch clinical trials of three newly identified positron emission tomography (PET) radiotracers. These include two targeting the alpha-synuclein protein, a hallmark of Parkinson’s and multiple system atrophy, and one for 4-repeat tau, a marker associated with frontotemporal degeneration and progressive supranuclear palsy. Using a computational chemistry tool developed at the University of Pennsylvania, researchers evaluated millions of molecules to pinpoint those most likely to bind effectively to specific toxic proteins. This innovative approach enabled the selection of these radiotracers, which are designed to help visualize protein aggregates in the brain via PET scans. These imaging tools have the potential to significantly enhance early diagnosis, monitor disease progression, and assess responses to treatment, similar to how beta-amyloid tracers have transformed Alzheimer’s care. The consortium, which unites experts from institutions such as the University of California San Francisco, the University of Pittsburgh, Washington University in St. Louis, and Yale University, represents a collaborative effort to address the complexities of developing effective PET tracers. Over the next five years, these clinical trials aim to validate the utility of these radiotracers, paving the way for broader applications in diagnosing and managing a range of neurodegenerative diseases. Researchers also hope that the computational tool used in this process will streamline the development of future tracers, accelerating progress in neurological imaging and care.